Aeglea Biotherapeutics appoints Hunter Smith to board of directors and audit committee

Spyre Therapeutics, Inc.

Hunter Smith appointed as Class I director and Audit Committee member effective November 12, 2021.
Smith is CFO of Rhythm Pharmaceuticals (since July 2017) and previously VP Finance at Celgene.
Receives pro rata director retainer ($40,000 annual) and audit committee retainer ($7,500 annual).
Granted option to purchase 60,000 shares at closing price on November 12, 2021, vesting monthly over three years.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hunter Smith

Class I Director

SYRE · Spyre Therapeutics, Inc.

Effective: 2021-11-12
Filed: November 16, 2021, 6:59 PM ET

On November 12, 2021, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Hunter Smith as a Class I director and as a member of the Audit Committee, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Hunter Smith was appointed as Class I Director at Spyre Therapeutics, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On November 12, 2021, the board of directors (the “Board”) of Aeglea Biotherapeutics, Inc. (the “Company”) appointed Hunter Smith as a Class I director and as a member of the Audit Committee, effective immediately.

View on SEC.gov

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001564590-21-057143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.